Unveiling the Future of Dermatology: GLP-1 Therapy, CSU Care, and Access Expansion
In a thought-provoking session at Fall Clinical 2025, renowned dermatologist Marc Serota, MD, unveiled the transformative trends in dermatology that will define the year ahead. Serota's insights shed light on the integration of GLP-1 therapy, advancements in chronic spontaneous urticaria (CSU) management, and the evolving landscape of care delivery.
The Role of GLP-1 Therapy in Psoriasis Management
Dr. Serota emphasized the importance of recognizing obesity as a chronic inflammatory condition that often exacerbates psoriasis. He stated, 'When patients present with psoriasis plaques and obesity, it's crucial to understand the role of adipocytes in skin inflammation.' GLP-1 receptor agonists, he explained, not only promote weight loss but also indirectly reduce psoriasis activity by targeting adipose tissue and inflammatory signaling.
CSU Management: A Dermatology Focus
The discussion turned to the resurgence of CSU management within dermatology practices. Serota highlighted the shift in understanding CSU, from an external allergic trigger to an autoallergic or autoimmune process. He stated, 'CSU diagnosis and treatment can now be managed within the dermatology office, offering patients relief from chronic hives.' While omalizumab has been a longstanding treatment, newer options like dupilumab and remibrutinib provide dermatologists with directed therapies, ensuring effective management.
Hybrid Care Models: Balancing Virtual and In-Person Care
Looking ahead, Serota emphasized the importance of hybrid care models in 2026. The COVID-19 pandemic accelerated telehealth adoption, but the industry is now finding a balance between virtual and in-person care. He stated, 'Partnerships between pharmaceutical companies, employers, and health systems are expanding access to board-certified specialists via telemedicine.' This approach allows for routine care to be conducted virtually while reserving in-person visits for procedures and complex cases, ensuring a comprehensive and patient-centric approach.
Conclusion: Embracing the Future of Dermatology
As the session concluded, Dr. Serota left the audience with a powerful message, encouraging them to embrace these transformative trends. He stated, 'The future of dermatology is about integrating innovative therapies, expanding access, and providing comprehensive care. By recognizing the interconnectedness of metabolic and dermatologic aspects, we can achieve better outcomes for our patients.'
For those eager to stay ahead of the curve, Dermatology Times offers a valuable resource. Subscribers can receive weekly updates on therapies, innovations, and practical tips, ensuring they remain informed about the latest advancements in dermatology.
